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INTRODUCTION
Statins are the most prescribed class of 
medicine in England1 with >70 million 
statin prescriptions issued each year,2 and 
they play an important role in the primary 
prevention of cardiovascular disease (CVD). 
The predicted benefit of taking statins is 
proportional to the estimated risk of CVD,3 
but the potential harms and costs are 
independent of CVD risk. Therefore, there 
is a risk threshold where the predicted 
benefits outweigh the harms, and statins 
can be recommended. Because of this, the 
estimation of CVD risk is a fundamental 
part of clinical guidance on CVD prevention 
around the world.4–7 In England and Wales, 
the risk threshold for offering treatment 
was a 20% 10-year risk until 2014, when 
it was lowered to a 10% 10-year risk.7,8 
The effective utilisation of risk scoring 
improves accuracy of CVD risk predictions 
and increases medical prescribing with 
no evidence of clinical harm.9–11 Moreover, 
because communication of the risks and 
benefits of treatment options is a necessary 
component of shared decision making, an 
accurate CVD risk estimate is an essential 
part of effective clinical decision making. 
However, patients are often initiated on 
statins when their estimated CVD risk is 
below the recommended threshold,12–16 
suggesting that prescribing decisions are 
not wholly based on risk estimates. One 
reason for this is a focus on individual 
risk factors: the ‘heuristic that identifies 
elevated cholesterol as a medical problem 
in its own right’.17 One US study showed 
single risk factor management strongly 
influenced statin prescribing,18 and a 
randomised theoretical experiment in 
Australia highlighted clinicians’ preferences 
for managing individual risk factors over 
absolute risk.19 This preference is consistent 
with observational data, which showed that 
statin initiation in Australia was largely 
unrelated to CVD risk, whereas in New 
Zealand it was more aligned to CVD risk.20 
Other reasons that clinicians may not use 
risk scores include a belief that risk scoring 
oversimplifies the decision and may lead 
to overprescribing21 and confusion about 
how best to use risk score calculators.22 
Finally, patients find it difficult to make 
decisions based on future risks and tend 
to preferentially focus on cholesterol levels 
when considering taking statins,23,24 which is 
likely to influence clinical decision making.
This study explores the prescribing of 
statins for the primary prevention of CVD 
in England and Wales. Previous research16 
has shown low rates of coding of estimated 
CVD risk (QRISK2),25 so this study utilises 
post-hoc risk estimates to allow for the 
possibility that clinicians calculate, but do 
not code, estimated CVD risk, nor estimate 
CVD risk using clinical judgement. This also 
enables investigation of whether the act of 
coding estimated CVD risk is associated 
with prescribing informed by CVD risk. 
By focusing on untreated patients with a 
coded lipid result, the period of CVD risk 
assessment and potential consideration of 
Abstract
Background
Initiation of statins for the primary prevention of 
cardiovascular disease (CVD) should be based on 
CVD risk estimates, but their use is suboptimal.
Aim
To investigate the factors influencing statin 
prescribing when clinicians code and do not 
code estimated CVD risk (QRISK2).
Design and setting
A historical cohort of patients who had lipid tests 
in a database (IQVIA Medical Research Data) of 
UK primary care records. 
Method
The cohort comprised 686 560 entries (lipid test 
results) between 2012 and 2016 from 383 416 
statin-naive patients without previous CVD. 
Coded QRISK2 scores were extracted, with 
variables used in calculating QRISK2 and factors 
that might influence statin prescribing. If a 
QRISK2 score was not coded, it was calculated 
post hoc. The outcome was initiation of a statin 
within 60 days of the lipid test result.
Results
Of the entries, 146 693 (21.4%) had a coded 
QRISK2 score. Statins were initiated in 6.6% (95% 
confidence interval [CI] = 6.4% to 6.7%) of those 
with coded and 4.1% (95% CI = 4.0% to 4.1%) 
of uncoded QRISK2 (P<0.001). Statin initiations 
were consistent with National Institute for Health 
and Care Excellence guideline recommendations 
in 85.0% (95% CI = 84.2% to 85.8%) of coded and 
44.2% (95% CI = 43.5% to 44.9%) of uncoded 
QRISK2 groups (P<0.001). When coded, QRISK2 
score was the main predictor of statin initiation, 
but total cholesterol was the main predictor 
when a QRISK2 score was not coded.
Conclusion
When a QRISK2 score is coded, prescribing 
is more consistent with guidelines. With no 
QRISK2 score, prescribing is mainly based on 
total cholesterol. Using QRISK2 is associated 
with statin prescribing that is more likely to 
benefit patients. Promoting the routine CVD 
risk estimation is essential to optimise decision 
making.
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statin treatment is observed. This enables 
a greater understanding of the way GPs 
make decisions in practice and how risk 
scoring influences prescribing decisions. 
The objective of this study, therefore, is 
to identify the factors influencing statin 
prescribing when clinicians code, and do not 
code, estimated cardiovascular disease risk.
METHOD
This was a historical cohort study using 
data from an anonymised database 
of primary care records for practices in 
England and Wales contributing to IQVIA 
Medical Research Data (IMRD)-UK (formally 
The Health Improvement Network). 
IMRD contains routine patient data from 
>500 general practices, and is generalisable 
to the UK population.26 Practices contributing 
to IMRD use the Vision (In Practice Systems) 
electronic patient records system.27 Clinical 
classification version 2 Read codes are 
used for clinical data28 and British National 
Formulary (BNF) drug codes for prescribing 
data.29
To maintain a stable cohort of practices, 
only IMRD practices contributing data for 
the whole study period from the beginning 
of 2012 to the end of 2016 were included. 
Patients registered in an IMRD practice, 
aged 40–85 years, with a lipid result, and 
without a previous statin prescription were 
eligible for inclusion. The lower age cut-off 
was chosen to correspond with the start 
of NHS Health Check eligibility, and the 
upper limit was chosen to correspond to 
the maximum age where QRISK2 can be 
used. Exclusion criteria included existing 
CVD, familial hypercholesterolaemia, and 
pregnancy (see Box 1 for full list). Patients 
without 60 days of follow-up were also 
excluded. An individual patient with multiple 
lipid results may enter the cohort multiple 
times. The unit of analysis is an entry (an 
occasion when statins might be prescribed) 
rather than an individual patient.
Demographic data on practice identifier, 
ethnicity, Townsend deprivation quintile,30 
sex, and age were extracted. For missing 
data a ‘missing’ category was used. The 
lipid values were extracted, along with any 
variables that are included in the QRISK2 
calculation or could influence statin 
prescribing (see protocol paper31 for full 
list). Biologically implausible values were 
excluded (including cases where high-
density lipoprotein [HDL] cholesterol was 
greater than total cholesterol [TC]).
Any QRISK2 score coded from the date 
of the lipid result to 60 days later was 
extracted. The follow-up period was 60 days 
from the index date (the date of the lipid 
result being coded, or the date of QRISK2 
score coding). The follow-up period was 
chosen as a time period during which it 
would be considered clinically reasonable 
that the decision to start a statin was related 
to the lipid measurement or the coded 
QRISK2 score. The date of QRISK2 coding 
was used as this demonstrates clinical 
interaction with the lipid result, and hence 
can be taken as a point where management 
decisions are made. In the absence of a 
coded QRISK2 score, it was assumed that 
the clinician filing the lipid result would act 
on this information at this time.
Analysis
The dataset was divided into two groups: 
cohort entries with a QRISK2 score coded 
0–60 days after the lipid result, and those 
without. A post-hoc QRISK2 score was 
calculated for each entry into the cohort 
using their risk factor data. Where variables 
were missing, the QRISK2 calculator default 
values were used in the same way as they 
would in clinical practice. 
The cohort was described, including 
mean lipid values, QRISK2 scores, and 
the proportion of entries resulting in a 
statin prescription. The coded or post-hoc 
calculated QRISK2 scores were used to 
assess if statin initiation was indicated 
according to National Institute for Health 
and Care Excellence (NICE) guidelines 
(10-year QRISK2 score ≥20% pre-2014 
and ≥10% post-2014). The proportion of 
indicated and non-indicated statin initiations 
were calculated for those with and without 
a coded QRISK2 score. Because changes 
to guidelines were announced prior to their 
publication, and to allow for a dissemination 
How this fits in 
Estimated cardiovascular disease risk 
provides the best guide to the benefits 
of using statins for primary prevention. 
However, it is not always carried out prior 
to initiation of statins, which brings into 
question how statin initiation decisions are 
made. By focusing on the period of time 
following a lipid test, it was found that, 
when cardiovascular risk is calculated and 
coded, the prescribing decision-making 
process is clearly different from when 
cardiovascular risk is not coded. When risk 
estimates are coded, statin prescribing is 
much more aligned with clinical guidance. 
But, when risk estimates are not coded, 
prescribing is mainly influenced by total 
cholesterol levels and therefore more 
discordant with guidance.
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Box 1. Cohort inclusion and 
exclusion criteria
Inclusion criteria 
 Age 40–85 years 
  Lipid result coded (at least TC and HDL) in 
study period 
No previous statin prescriptions
Exclusion criteria 
 Existing CVD 
 Chronic kidney disease stage ≥3 
 Type 1 diabetes mellitus 
 Hypercholesterolaemia 
 Pregnancy 
 Incomplete follow-up (60 days)
Dates defining eligibility  
Latest of: 
 Study start date 
 Acceptable mortality reporting date 
 Vision installation date plus 1 year 
 Registration date plus 1 year 
 40th birthday
Until earliest of: 
 85th birthday 
 Study end date 
 New CVD diagnosis 
 New statin initiation 
 New recording of a contraindication  
  to the prescribing of statins 
 Death 
 Transfer out of the practice
CVD = cardiovascular disease. HDL = high-density 
lipoprotein. TC = total cholesterol. 
period after their publication, data from 2014 
were excluded in this part of the analysis as 
it is difficult to define an exact date on which 
general practices transitioned from one 
guideline to the other.
A multivariable logistic regression model 
was fitted to model statin initiation. The 
initial full model included all the covariates 
in the QRISK2 score, the calendar year, and 
TC. All continuous covariates were included 
as multiple fractional polynomials in order 
to establish their functional form.32 Discrete 
Bernoulli or ordinal variables were included 
in their original form. The outcome was the 
prescription of a statin within 60 days. 
There were three steps to the elimination 
of covariates to derive the eventual model:
1.  Backward elimination was used to 
remove insignificant covariates (P>0.05) 
to produce an initial fixed-effects model. 
2.  A random intercept for the practice 
identifier (ID) was then introduced and 
insignificant variables were identified 
and eliminated. 
3.  If no insignificant variables were 
identified at step 2, the resulting mixed-
effects model was the reduced model 
adopted. 
If insignificant covariates were identified 
then steps 1 and 2 were repeated until there 
were no insignificant variables at step 2. 
The resulting model was described for the 
coded and uncoded groups. To indicate the 
discriminative and predictive ability of the 
models, receiver operating characteristic 
(ROC) curves and calibration plots (using 
LOESS smoothing) were derived.33
Finally, the prescribing pattern of the 
coded group was applied to the uncoded 
group to estimate the rates of statin 
prescribing if the uncoded group behaved 
in the same way as the coded group. All 
statistical analyses were conducted in R 
(version 3.5.2).
RESULTS
There were 686 560 entries into the 
cohort from 383 416 individual patients 
and 227 separate practices. Of these, 
146 693 entries (21.4%; 95% confidence 
interval [CI] = 21.3% to 21.5%) (n = 128 009 
individual patients) had a coded QRISK2 
score 0–60 days after coding of the lipid 
result (see Supplementary Table S1 for 
details). The proportion of entries where a 
QRISK2 score was coded increased over the 
study period but remained well below one-
third (Figure 1). The groups were broadly 
similar, although there were higher levels 
of comorbidity, obesity, and older patients 
in the uncoded group (see Supplementary 
Tables S1 and S2). The higher mean QRISK2 
score in the uncoded group is largely due to 
the differences in age between the two 
groups, with 10.3% of the coded group 
being ≥70 years old compared with 16.3% 
of the uncoded group. There were also 
significantly fewer lipid tests per patient 
in the coded versus uncoded groups (1.15 
versus 2.11 tests per patient; P<0.01).
There was good agreement between 
calculated and recorded QRISK2 scores 
(R 2 = 0.874). Overall, a statin was initiated 
within 60 days of the index date for 4.6% 
(95% CI = 4.6% to 4.7%) of entries, and 
30.5% (95% CI = 30.0% to 31.0%) of these 
initiations had a coded QRISK2 score. Statin 
initiations were more common among the 
entries with a coded QRISK2 score (6.6%; 
95% CI = 6.4% to 6.7%) compared with 4.1% 
(95% CI = 4.0% to 4.1%) in the uncoded 
group (P<0.001) (see Supplementary 
Table S1). 
Entries in the coded group were more 
likely to be prescribed a statin when it 































Figure 1. Percentage of entries with a coded QRISK2 
score by year.
Table 1. Rates of initiation according to whether statins would be 
indicated according to prevailing guideline
Groupa Indication Statin initiated, n (%) Statin not initiated, n (%) Total, n
Uncoded Indicated 7550 (6.2) 114 471 (93.8) 122 021
 Not indicated 9532 (3.2) 291 448 (96.8) 300 980
 Total 17 082 (4.0) 405 919 (96.0) 423 001
Coded (indication by Indicated 6252 (19.2) 26 243 (80.8) 32 495 
calculated QRISK2) Not indicated 1959 (2.3) 82 821 (97.7) 84 780
 Total 8211 (7.0) 109 064 (93.0) 117 275
Coded (indication by Indicated 6978 (19.2) 29 286 (80.8) 36 264
coded QRISK2) Not indicated 1233 (1.5) 79 778 (98.5) 81 011
 Total 8211 (7.0) 109 064 (93.0) 117 275
aExcluding the 146 284 entries from 2014.
was indicated than the uncoded group (risk 
ratio [RR] = 3.11, 95% CI = 3.02 to 3.21) 
(Table 1). In the uncoded group, 44.2% (95% 
CI = 43.5% to 44.9%) of statin prescriptions 
were indicated in accordance with NICE 
criteria compared with 85.0% (95% 
CI = 84.2% to 85.8%) of statin prescriptions 
in the coded group (RR = 1.92, 95% CI = 1.89 
to 1.96). In both groups, the proportion of 
entries prescribed a statin when it was 
indicated was low (6.2% when QRISK2 was 
not coded, 19.2% when it was) (Table 1).
In the regression analysis for entries 
with a coded QRISK2 score, the QRISK2 
score was the most important variable in 
explaining the variation in statin prescribing 
(see Supplementary Table S3 for details), 
followed by TC. The other contributing 
variables (in order of contribution) were 
type 2 diabetes, TC/HDL ratio, hypertension, 
year, rheumatoid arthritis, Townsend 
deprivation quintile, smoking status, and sex. 
In the regression model for entries without 
a coded QRISK2 score, TC was by far the 
most important predictor, followed by type 2 
diabetes and then (post-hoc) QRISK2 score. 
TC/HDL ratio, sex, age, body mass index 
(BMI), hypertension, smoking status, atrial 
fibrillation, Townsend deprivation quintile, 
and family history of CVD also contributed 
with diminishing importance. Both models 
showed good discrimination and calibration 
(see Supplementary Figure S1 for details) 
with area under curves (AUC) of 0.864 
(95% CI = 0.861 to 0.868) and 0.838 (95% 
CI = 0.834 to 0.842), for the coded and 
uncoded models, respectively. Calibration 
of the models is poorer at higher predicted 
probabilities of statin prescribing owing 
to the low number of entries with these 
predicted probabilities.
Using the model created for the coded 
group, the distributions of predicted 
probabilities (of statin initiations) for the two 
groups are very similar (see Supplementary 
Figure S2 for details). Therefore, it is 
possible to estimate what the effects on 
statin prescribing would be if GPs had 
coded QRISK2 scores in the uncoded group. 
If this were the case, the number of statin 
initiations (excluding 2014) would increase 
from 17 082 (4.0%) to 27 943 (6.6%) and 
the proportion of prescriptions that are 
consistent with NICE guidelines would 
increase from 44.2% to 83.8%. 
Figure 2 illustrates the effects the 
TC level has on the probability of being 
prescribed a statin for a patient with a 
QRISK2 score of 4.6% in both the coded 
and uncoded groups. It can be seen that 
statin initiation is increasing likely above 
the standard ’upper limit of normal’ of 
5.0 mmol/l but this arbitrary threshold has 
much less impact when a QRISK2 score is 
coded. The increasing probability of a statin 
being prescribed with increasing TC, but a 
constant QRISK2 score, is illustrated for two 
clinical scenarios in Table 2.
DISCUSSION
Summary
This study has demonstrated for the first 
time that coding of a QRISK2 score following 
a lipid test is associated with markedly 
different prescribing behaviour. On most 
occasions a QRISK2 score is not coded, 
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Table 2. Illustrative case
Case 1a Case 2a
White, 50-year-old male White, 60-year-old male
TC/HDL = 4.0 TC/HDL = 4.2 
Systolic BP = 130 mmHg Systolic BP = 155 mmHg
Non-smoker Heavy smoker
Actual QRISK2 score = 4.6%  Actual QRISK2 score = 20.3% 
  
 Case 1 (QRISK2 score = 4.6%) Case 2 (QRISK2 score = 20.3%)
 TC = 4.2 mmol/L TC = 7.0 mmol/L TC = 4.2 mmol/L TC = 7.0 mmol/L
QRISK2 coded; 0.3 2.0 9.5 39.7 
probability of statin 
being prescribed, %
QRISK2 not coded; 0.1 6.1 0.7 19.3 
probability of statin 
being prescribed, %
aYear set to 2016. BP = blood pressure. HDL = high-density lipoprotein. TC = total cholesterol.
Figure 2. Probability of being prescribed a statin for 
a theoretical patient with a QRISK2 score of 4.6% but 
different TC levels, shown for both QRISK2 coded or 
uncoded scenarios. 


































but, when it is, clinicians prescribe more 
statins and, perhaps more importantly, 
prescribing is twice as likely to be consistent 
with guidelines. When it is coded in the 
record, estimated CVD risk is the strongest 
predictor of statin prescribing, but, when 
it is not, TC level and diabetic status are 
the strongest predictors. This supports 
the hypothesis that, when a QRISK2 score 
is not coded, clinicians are not making 
use of estimated CVD risk to inform their 
prescribing decision. If they are calculating 
or using clinical judgement to estimate 
risk then these findings suggest that their 
estimate is inaccurate, and determined 
mainly by TC level and diabetic status. The 
relative importance of a diagnosis of type 2 
diabetes in prescribing decisions (when 
QRISK2 is not coded) may be a result of 
targets within the Quality and Outcomes 
Framework,34 which incentivised GPs to 
reduce TC levels in these patients.
When the QRISK2 score is low, the 
probability of being prescribed a statin is 
similar in those with and without a coded 
QRISK2 score and, in both cases, it is 
predicted by TC levels (Table 2). Measured 
TC level affects the probability of a statin 
being prescribed in both those below 
and above the NICE treatment threshold, 
indicating that TC levels influence 
prescribing decisions over and above their 
effect on QRISK2 score. 
It is notable that patients in the uncoded 
group had considerably more entries per 
patient than the coded group (that is, they 
had their lipids measured more often before 
being prescribed a statin or leaving the 
cohort). This may be another indication of 
the difference in the way these patients’ GPs 
are managing CVD risk; perhaps repeating 
lipids until they get to a treatment threshold 
or focusing on lifestyle measures to reduce 
cholesterol. Further research would be 
required to unpick this finding.
Strengths and limitations
This study examines a large, representative 
sample of general practice in England and 
Wales. A post-hoc QRISK2 calculation, 
which correlates well with coded risk 
estimates, enables a direct comparison of 
the difference in decision making between 
encounters where a QRISK2 score is coded 
and those where it is not. This helps to 
establish the role of risk estimation in 
prescribing decisions, and allows insight 
into the role of CVD risk on decision making 
when it is not coded. By choosing lipid 
measurement as the cohort entry criteria, 
it is possible to model a clinically coherent 
decision-making process. Additionally, 
using empirical data on prescribing gives 
a strong indication of decision-making 
processes while avoiding the social or 
professional acceptability bias that might 
arise if clinicians were asked to describe 
their decision-making processes.
In this study it is assumed that prescribing 
decisions were based on the data coded in 
the electronic patient record. It is felt that 
the timeframe chosen represents a clinically 
plausible duration where clinical decisions 
may be linked with the coded data. It has 
been assumed that, when a QRISK2 score 
was not coded, neither was it calculated. 
Although this cannot be verified, the different 
factors associated with prescribing between 
the two groups appear to corroborate this 
assumption. It is possible, however, that 
some clinicians calculated, but did not code, 
a risk score. Additionally, some patients may 
have been prescribed a statin without having 
their lipids measured, and therefore would 
not have been entered into the study cohort 
— it is not possible to gain insight into this 
decision-making process.
It is not possible to explain why patients 
are not started on statins, other than to 
state that those without a coded QRISK2 
score would have been more likely to have 
a statin prescribed if they had a QRISK2 
score coded. Patients may not have been 
offered statins, may have declined them, or 
may have decided to delay the decision to a 
later date.
The data used do not allow clinician-level 
analysis. It is possible that one of the main 
determinants of the use of risk estimates 
is clinician heuristics. It could also be 
that practice-level systems and culture 
drive prescribing decisions, as has been 
demonstrated in other literature.35 Further 
understanding of these influences would 
help guide interventions for improvement. 
Comparison with existing literature
As previously reported, a significant 
proportion of statin initiations are to people 
with low estimated CVD risk.15,16 The use 
of a CVD risk score (as indicated by the 
coding) was associated with an increase in, 
and more accurate prescribing of, statins. 
This is consistent with a systematic review 
into the impact of estimated CVD risk.11 
Similarly, many patients with elevated CVD 
risk were not subsequently initiated on a 
statin, which is consistent with previous 
research.15,16
In contrast with other research,21 it was 
found in this study that lack of CVD risk 
scoring, rather than use of CVD risk scoring, 
was associated with overprescribing in 
those at low risk, and oversimplification of 
5  British Journal of General Practice, Online First 2021
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the decision through focusing on single risk 
factors. The dominance of single risk factors 
over global risk estimates in influencing 
statin prescribing has been previously 
reported.18,19,36 This focus on individual 
risk factors (specifically TC) is perhaps 
understandable, in part because patients 
prefer to focus on immediate problems and 
single risk factors rather than estimates of 
future risk.23,37
Implications for research and practice
A significant proportion of statin initiations 
still seem to be based on cholesterol 
levels. More work needs to be done in 
understanding why this is and on how to 
change practice to focus the attention of 
clinicians, and patients, onto CVD risk rather 
than single risk factors. Risk estimation 
should be the cornerstone of statin initiation 
decisions both in deciding which patients 
should be offered a statin, and as a basis 
for shared decision making thereafter. 
CVD risk scoring is strongly associated 
with guideline-concordant prescribing. 
Either consultations where GPs are more 
likely to follow guidelines lead them to 
record QRISK2 scores, or recording QRISK2 
scores leads GPs to be more likely to follow 
guidelines. If part of the explanation is the 
latter, then intervention to increase the 
recording of QRISK2 scores would increase 
guideline concordance. 
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